文献速递神经肿瘤

MRI增强扫描在弥漫性和间变性胶质瘤中的诊断价值

The diagnostic value of contrast enhancement on MRI in diffuse and anaplastic gliomas.
PubMed 文献 · Acta Neurochir (Wien) · 2022-01-11

该回顾性研究从前瞻性数据库纳入99例首次切除的WHO II级和III级胶质瘤患者,用容积分割测量术前T1加权MRI的钆增强体积。间变性胶质瘤检出增强的OR为弥漫性胶质瘤的7倍(95%CI 2.8-17.2,p<0.0001);50%(8/16)局灶间变性和28%(10/36)完全间变性胶质瘤无增强,21%(10/47)弥漫性胶质瘤有增强。

要点

  • 间变性胶质瘤检出增强的OR为弥漫性胶质瘤的7倍(95%CI 2.8-17.2,p<0.0001)。
  • 50%(8/16)局灶间变性和28%(10/36)完全间变性胶质瘤无增强。
  • 21%(10/47)弥漫性胶质瘤存在增强。

核心结论

  • 增强与间变、IDH1野生型和ATRX表达等不良预后特征的高比值比相关。
  • 四分之一间变性胶质瘤和一半局灶间变性胶质瘤无增强。

研究设计与样本

  • 回顾性从前瞻性数据库检索99例首次切除的WHO II级和III级胶质瘤患者。
  • 用容积分割测量术前T1加权MRI的钆增强体积。

主要发现

  • 间变性胶质瘤检出增强的OR为弥漫性胶质瘤的7倍(95%CI 2.8-17.2,p<0.0001)。
  • 50%(8/16)局灶间变性和28%(10/36)完全间变性胶质瘤无增强。
  • 21%(10/47)弥漫性胶质瘤存在增强。
  • 间变与更大的增强体积相关(r=0.49,p<0.0001),相比完全弥漫性肿瘤额外提供4 cm3增强体积。
  • IDH1野生型肿瘤有增强的OR为3.6倍(95%CI 1.3-10.2,p=0.05),ATRX表达肿瘤为4.8倍(95%CI 1.3-17.2,p=0.05)。

关键数值与推荐

  • 间变性胶质瘤检出增强的OR为7(95%CI 2.8-17.2,p<0.0001),对比弥漫性胶质瘤。
  • IDH1野生型肿瘤有增强的OR为3.6(95%CI 1.3-10.2,p=0.05)。
  • ATRX表达肿瘤有增强的OR为4.8(95%CI 1.3-17.2,p=0.05)。
  • 间变与增强体积相关r=0.49(p<0.0001),额外4 cm3增强体积对比完全弥漫性肿瘤。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We evaluated differentiations in gadolinium contrast enhancement (CE) between low-grade WHO °II and high-grade WHO °III gliomas in conventional MRI, which have been repeatedly questioned. METHODS: Ninety-nine patients, who underwent first resection of WHO°II and °III gliomas, were retrospectively retrieved from a prospective database. The quantitative metric volume of Gd-CE in T1-weighted pre-operative MRI was measured using volumetric segmentation. RESULTS: The OR to detect CE in anaplastic gliomas was seven times higher than that in diffuse gliomas (CI95% 2.8-17.2, p<0.0001). No CE was seen in 50% (8/16) of focal anaplastic and in 28% (10/36) of entirely anaplastic gliomas. CE was present in 21% (10/47) of diffuse gliomas. Anaplasia correlated with a larger CE volume (r=0.49, p<0.0001) and provided additional 4 cm3 of CE volume compared to entirely diffuse tumors. The OR to have CE was 3.6 times for IDH1 wild-type tumors (CI95% 1.3-10.2, p=0.05) and 4.8 for tumors with ATRX expression (CI95% 1.3-17.2, p=0.05). In all sub-groups, at least a quarter of cases showed no CE at all and there were cases with present CE. CONCLUSION: CE is associated with higher odds of unfavorable prognostic features like anaplasia, wild-type IDH1 and retained ATRX. There was no CE in one-fourth of anaplastic gliomas and half of gliomas with focal anaplasia.

来源:Acta Neurochir (Wien),查看原文。版权归原作者所有。

引用

  1. Krigers A, Demetz M, Grams AE, et al. The diagnostic value of contrast enhancement on MRI in diffuse and anaplastic gliomas. Acta Neurochir (Wien). 2022. PMID: 35018531. doi:10.1007/s00701-021-05103-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。